Pressure is again mounting on the Chilean government to take measures that would allow generic versions of hepatitis C drugs formulated with Gilead Sciences Inc.’s sofosbuvir to enter the market. Law makers in the country’s lower house of Congress have backed a resolution calling on the government to move ahead with issuing compulsory licenses.
On Jan. 2, the chamber of deputies voted in support of resolution 1014, which calls on the health minster to...




